Increasing access to vaccines
SaponiQx is a cutting edge bio-pharmaceutical company with a vision of protecting the health of populations worldwide. We seek to enable the development of safe and effective vaccines through the expansion of access to saponin based adjuvants.
QS-21 STIMULON™: a proven adjuvant
SaponiQx’s proprietary saponin QS-21 STIMULON is a crucial component of the adjuvant in GSK’s FDA-approved Shingrix vaccine
Improve
Efficacy
Helps elicit a more powerful immune response for greater protection
Extend
Protection
Provides longer lasting protection through a high quality immune response
Reduce
Cost
Conserving antigen using an adjuvant can dramatically reduce total vaccine cost
About SaponiQx
Vision
Making critical adjuvants broadly available for
life-saving vaccines
Team
Success in vaccine development across industry, government, and academia
Proven Product
QS-21 is a potent adjuvant component utilized in multiple approved vaccines
Adjuvant Pipeline
Designing bespoke adjuvants to target specific immune responses
Manufacturing Platform
Secure and scalable supply chain for improved quality and access to QS-21
- Merck’s Zostavax market leader until 2018
- GSK released Shingrix in 2018 w/ Agenus QS-21 STIMULONTM
- Zostavax halted in 2020
- Shingrix “crown jewel” of GSK vaccine portfolio
Superior Efficacy
Superior Duration
Superior Cost Per Dose
SaponiQx was created around a compelling capability...
…the ability to sustainably manufacture the proven saponin adjuvant QS-21 STIMULONTM at commercial scale using cell culture instead of its limited natural source, Chilean tree bark.
SaponiQx's streamlined manufacturing process replaces a complex, risky, and expensive supply chain
Multiple facilities and countries; > 15 steps
Current Manufacturing Process
(Bark Extract)
One site; > 7 steps
Manufacturing Process
(Cell Extract)
Explore our stories
Get a glimpse of how we work to improve lives
